SecBot SecBot
PRESS-RELEASE ·Filed Mar 18, 2026

MRKR

Marker Therapeutics
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Traders should monitor the upcoming Q2 2026 clinical data readouts for MT-601 in lymphoma and the initiation of the pancreatic cancer trial, which could serve as near-term catalysts. However, declining grant revenue and persistent losses raise funding risk beyond 2026 without dilution or new grants.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.32
T+0 close · Mar 18, 2026 · via day close
Latest settled
+4.55%
T+60 · $1.38
Vs SPY
−9.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $1.32entry
  2. T+1 · 8mo ago +1.52%α +3.26% · $1.34
  3. T+5 · 8mo ago +2.27%α +4.48% · $1.35
  4. T+20 · 7mo ago +25.76%α +18.14% · $1.66
  5. T+60 · 5mo ago +4.55%α −9.80% · $1.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower R&D spending, while maintaining a $17 million cash position expected to fund operations into Q4 2026. The company emphasized strong clinical progress, including a 66% objective response rate in lymphoma and promising pancreatic cancer data, with key updates expected in Q2 2026.

Key Financial Metrics

Revenue
$3.5M
-46.2% YoY
Adj. EPS
$-12163620.00
GAAP: $-12163620.00

Key Facts

  • Net loss widened to $12.2 million in 2025 from $10.7 million in 2024 despite lower R&D expenses ($11.8M vs $13.5M).
  • Cash, cash equivalents, and restricted cash totaled $17.0 million at year-end 2025, down from $19.2 million in 2024.
  • Cash runway expected through Q4 2026 without additional grant funding.
  • MT-601 showed 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with 50% complete responses.
  • Nature Medicine publication reported up to 84.6% disease control rate in pancreatic cancer with MT-601 combination therapy.
  • Company-sponsored pancreatic cancer trial expected to initiate in Q2 2026.
  • Grant income declined sharply to $3.5M in 2025 from $6.6M in 2024.

Financial Impact

Revenue declined 46% YoY to $3.5M due to lower grant income; net loss increased 13% despite cost reductions; cash burn was $12.0M in 2025.

revenuenet_losscash_positiongrant_income

Risk Factors

  • Limited cash runway extending only to Q4 2026 with no guarantee of additional grant disbursements.
  • Heavy reliance on non-dilutive funding; decline in grant income raises sustainability concerns.
  • Clinical-stage biotech risk: value hinges on unproven therapies with no near-term revenue potential.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258655

Track record

5 reports on MRKR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Oct 19, 202628d ago 8-K Bullish 5/10 Entry $1.20 to $0.8700 Now $0.8300 −30.83% ▼ −27.50% −24.04% vs SPY
  2. Oct 19, 202628d ago Press Release Bullish 5/10 Entry $1.20 to $0.8286 Now $0.8300 −30.83% ▼ −30.95% −27.49% vs SPY
  3. Mar 20, 202634w ago DEFA14A Neutral 4/10 Entry $1.31 to $1.56 Now $0.8300 −36.64% ▲ +19.08% +11.66% vs SPY
  4. Mar 19, 202634w ago 8-K Mixed 6/10 Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
  5. Mar 18, 202634w ago Press Release Mixed 6/10 Viewing Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 18, 2026